ATS 907

Drug Profile

ATS 907

Alternative Names: ATS907

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asahi Kasei
  • Developer Altheos
  • Class Antiglaucomas; Eye disorder therapies
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 31 Aug 2012 Altheos completes a phase IIa trial in Glaucoma & Ocular hypertension in USA (NCT01668524)
  • 16 Aug 2012 Phase-II clinical trials in Glaucoma in USA (Topical)
  • 16 Aug 2012 Phase-II clinical trials in Ocular hypertension in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top